sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
»ùÒòÐÞÊÎÐÔÖ¬·¾¸Î¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > »ùÒòÐÞÊÎÐÔÖ¬·¾¸Î¶¯ÎïÄ£×Ó

ǰÑÔ

Ö¬·¾¸Î(fatty liver disease,FLD)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔ­ÓÉÒýÆðµÄ¸ÎÔàÖ¬·¾´úлÕϰ­£¬Ö¬ÀàÎïÖʵĶ¯Ì¬Æ½ºâʧµ÷£¬¸Îϸ°ûÄÚÖ¬·¾Èº¼¯¹ý¶àµÄ²¡±ä ¡£Ö¬·¾¸ÎµÄ·¢²¡ÂʽüÄêÀ´Ñ¸ËÙÉÏÉý£¬ÒѳÉΪ½ö´ÎÓÚ²¡¶¾ÐÔ¸ÎÑ׵ĵڶþ´ó¸Î²¡£¬ÕýÑÏÖØÍþв¹úÈ˵Ŀµ½¡ ¡£Æ¾Ö¤²¡Òò£¬Ö¬·¾¸Î¿É·ÖΪ·Ç¾Æ¾«ÐԺ;ƾ«ÐÔÁ½´óÀà ¡£·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(nonalcoholic fatty liver disease, NAFLD)·¢²¡»úÖÆÏÖÔÚÉÐδÃ÷È·£¬ÖÎÁÆÉÏҲȱ·¦ÓÐÓò½·¥£¬ÊÇÏÖÔÚÑо¿µÄÖØµã ¡£¾Æ¾«ÐÔÖ¬·¾¸Î¶¯ÎïÄ£×ÓÒÔÒûʳÓÕµ¼ÎªÖ÷£¬¾Æ¾«¿Éʹ¶¯Îï¸ÎÔàÑõÏûºÄÂÊÔö¸ß£¬ÔöÌíѪñ¼ÑªµÄÑõÏûºÄ£¬´Ó¶øïÔÌ­¶ÔСҶÖÐÐĸÎϸ°ûµÄÑõ¹©£¬ÒýÆð¸ÃÇøÓòµÄ¸Îϸ°ûÍË»¯Ó뻵ËÀ£¬²¢±¬·¢Ö¬·¾±äÐÔ ¡£ÀíÏëµÄÖ¬·¾¸Î¶¯ÎïÄ£×ÓÓ¦ÓëÈËÀàÖ¬·¾ÐԸβ¡µÄÌØÕ÷ÏàËÆ£¬¼´²¡±äÉú³¤Àú³ÌÓÐÏà¶ÔÏÔ×ŵķ֯Ú£¬´Ó´¿´âÐÔÖ¬·¾¸Î¡¢Ö¬·¾ÐÔ¸ÎÑס¢¸ÎÏËά»¯ÖÁ¸ÎÓ²»¯£¬²¢ÇÒÓ¦¾ßÓÐÄ£×ÓÐγÉÂʸߡ¢éæÃüÂʵ͡¢ÔìÄ£ÒªÁìÇáÓ¯Ò×ÐС¢¶ÔʵÑéÖ°Ô±ÎÞº¦¡¢ÔìÄ£×èÖ¹ºó²¡±äÄæ×ª»ºÂý£¬±ãÓÚ¾ÙÐÐÒ©Îï¸ÉÔ¤ÊÔÑéµÈÌØµã ¡£ÏÖÔÚÒѾ­ÔÚ´óÊó¡¢É³Êó¡¢Ð¡Êó¡¢¼ÒÍúÍÖíµÈ¶¯ÎïÖÖÊôÀֳɵؽ¨ÉèÁËÖ¬·¾¸Î¶¯ÎïÄ£×Ó£¬ÕâЩ¶¯ÎïÄ£×ÓΪÃ÷È·Ö¬·¾¸Î·¢²¡»úÖÆ¡¢É¸Ñ¡Ò©ÎïµÈ»ù´¡ºÍÁÙ´²Ñо¿ÌṩÁ˺ܺõÄʵÑ鹤¾ß ¡£

FLD¶¯ÎïÄ£×ÓÖ÷Òª·ÖΪËÄ´óÀࣺ×Ô¾õÐÔÄ£×Ó£¬»ùÒòÐÞÊζ¯ÎïÄ£×Ó£¬Òûʳ¡¢Ò©Îï»ò¶¾ÎïÓÕµ¼Ä£×Ó£¬¸´ºÏÄ£×Ó£¨ÍŽáÓ¦ÓûùÒòÄ£×ÓºÍÓªÑøÄ£×Ó£© ¡£ËüÃÇÔÚ²î±ðµÄ²ãÃæÊ©Õ¹×÷Ó㬵«×îÖÕÖ÷ÒªÊÇͨ¹ýʹ¸ÎÔàÖ¬·¾ÊäÈ루ºÏ³É»òÉãÈ룩ÔöÌí»òÊä³ö£¨É¨³ý£©ïÔÌ­µÄÔ­ÀíÖÆ³É ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

Õë¶Ôµ÷ÖθÎϸ°ûÖ¬·¾´úлµÄÒªº¦»ùÒò£¬Í¨¹ý»ùÒòÐÞÊεÈÒªÁìÒýÆð¸ÎÔàÖ¬·¾´úлÔÓÂÒºÍÑõ»¯Ó¦¼¤£¬µ¼Ö¸ÎÔàÖ¬·¾ÊäÈëºÍÊä³öƽºâʧµ÷ ¡£

¡¾Ä£×ÓÌØµã¡¿£º

CD36Çóý(CD36-/-)СÊóÓÉÓÚ³¤Á´Ö¬·¾Ëá¿çĤתÔËʧµ÷£¬Ö¬·¾ËáÖü´æºÍʹÓÃïÔÌ­60£¥ÒÔÉÏ£¬ÍâÖÜѪÖÐÖ¬·¾Ëá¼°¸ÊÓÍÈýõ¥Ë®Æ½ÏÔÖøÉÏÉý£¬¹ý¶àµÄÖ¬·¾ËáתÔËÖÁ¸ÎÔ࣬Áè¼ÝÆäβ£­Ñõ»¯ÄÜÁ¦£¬ÒýÆð¸ÎÔàÖ¬ÖÊ´úлÔÓÂÒ¼°ÒȵºËضԿ¹£¬ÐγÉFLD ¡£

ÒÒõ£¸¨Ã¸AÑõ»¯Ã¸(acyl-coenzyme A oxidase, AOX)Çóý(AOX-/-)СÊó³¤Á´Ö¬·¾Ëá´úл¼°Ö¬·¾ËáβÑõ»¯Òì³££¬Éúºó1ÖÜ·ºÆðÉ¢ÔÚÐÔ¸ÎÔàÖ¬·¾±äÐÔ£¬2¸öÔÂʱ¸ÎÔàÖ¬·¾±ä³ÊÃÖÂþÐԸı䣬4~5¸öÔÂʱ¸Îϸ°û¹ýÑõ»¯Ã¸ÌåÔöÖ³Îï»î»¯ÊÜÌåα (peroxisome proliferator-activated receptor alpha,PPARa)ϸ°ûÉ«ËØP450 (cytochrome P450, CYP450)¡¢CYP4a10ºÍCYP4a14µÈ»ùÒò±í´ïÔöÇ¿£¬Åãͬ¹ýÑõ»¯ÇâˮƽÉý¸ß£¬6¡«7¸öÔÂʱ¸ÎÔàÖ¬·¾ËáÑõ»¯´ú³¥ÐÔÔöÇ¿£¬¸ÎÔàÖ¬·¾±ä¿ÉÄæ×ª£¬µ«15¸öÔÂʱ¿É²¢·¢HCA»òHCC ¡£

ÏßÁ£ÌåÈý¹¦Ð§ÂѰ×ø(mitochondrial trifunctional protein,MTP)Çóý(MTP-/-£©Ð¡ÊóѪÇåת°±Ã¸Ë®Æ½ËæÄêËêÔöÉϾÙÐÐÐÔÉý¸ß£¬9¡«10¸öÔÂʱ·ºÆð¸ÎÖ¬·¾±ä¡¢¸ßÒȵºËØÑªÖ¢¡¢ÒȵºËضԿ¹¼°ÌÇÄÍÁ¿ÊÜË𣬲¢°éÓиÎÔàÑõ»¯Ó¦¼¤ÔöÇ¿ ¡£

µ°°±ËáÏÙÜÕ×ªÒÆÃ¸1A (methionine adenosyl­transferase-1A, MAT1A)Çóý(MAT1A-/-)СÊó¸ÎÔà¹Èë׸Êëĵȿ¹Ñõ»¯¼Áº¬Á¿½µµÍ£¬¼ÓÈëÖ¬ÖÊÑõ»¯µÄCYP 4a10ºÍ4a14»ùÒò±í´ïϵ÷ ¡£3¸öÔÂʱ·ºÆðÖ¬·¾¸Î¡¢¸Î´ó£¬8¸öÔÂʱ·ºÆð×Ô¾õÐÔÖ¬·¾ÐÔ¸ÎÑ׺ÍÞ²ÂöÖÜΧÑ×Ö¢£¬¸Îϸ°ûÔöÖ³ÏÔ×ÅʱÉõÖÁ¿ÉÄܱ¬·¢HCC ¡£MAT1A-/-СÊó¿ÉÓÃÓÚ̽ÌÖMAT1AÔÚ¸Îϸ°ûÔöÖ³¡¢ËðÉËÒÔ¼°¸ÎÖ×ÁöÐγÉÖеÄ×÷Óà ¡£

¸ÎÔàÌØÒìÐԺ˺ôÎüÒò×Ó1(nuclear respiratory factor 1, NRF1)Çóý(NRF1-/-£©Ð¡Êó4ÖÜÁäʱ·ºÆðÖ¬·¾ÐÔ¸ÎÑײ¢°éÓÐѪÇå¸ÊÓÍÈýõ¥Ë®Æ½Éý¸ß£¬4¸öÔÂʱ²¢·¢Ï¸°ûÖÜΧÏËά»¯£¬10¸öÔÂʱÔò¿É·ºÆðHCA»òHCC ¡£NRF1-/-СÊó¸Îϸ°û»îÐÔÑõˮƽ¡¢Ö¬·¾º¬Á¿ºÍDNAÑõ»¯Ôö¸ß£¬ÊÊÓÃÓÚÑо¿NAFLD·Ö×Ó»úÖÆ¼°ÆäÓëHCCµÄ¹ØÏµ ¡£

¸ÎÔàÌØÒìÐÔPTENÇóý(PTEN-/-)СÊóÔÚ³öÉúºó10ÖÜ¡¢35~40ÖÜ¡¢44ÖÜ¿ÉÏà¼Ì±¬·¢Ö¬·¾ÐÔ¸ÎÑ׸ÎÏËά»¯ÒÔ¼°¸ÎÏÙÁö ¡£74~78ÖÜ66£¥µÄСÊó»á²¢·¢HCC ¡£

Á×ËáÏ©´¼Ê½±ûͪËáôȼ¤Ã¸£­¹Ì´¼µ÷ÀíÒò×ÓÍŽáÂѰ×-1a (phosphoenolpyruvate carboxykinase-sterol regulatory-element binding protein 1a,PEPCK-SREBp­1a)СÊóÓÉÓÚ¸Îϸ°ûÌØÒìÐÔÌ«¹ý±í´ïSREBP-1a£¬³öÉúºó¼´±¬·¢ÔÝʱÐÔÖ¬·¾¸Î ¡£¶ÏÄ̺ó¸øÓèµÍ̼ˮ»¯ºÏÎï¡¢¸ßÂѰ×ÖÊÒûʳ¼¤»îPEPCK£¬ÓÕµ¼¶àÖÖÖ¬·¾ÌìÉúø£¬Ð¡ÊóÔÙ´ÎÐγÉÖ¬·¾¸Î ¡£aP2-NSREBP- 1cСÊóÓëPEPCK-SREBp-1aСÊó±íÐÍÏàËÆ ¡£

 

²Î¿¼ÎÄÏ×£º

1.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000

2.Farrell GC, van Rooyen D. Liver cholesterol: is ii playing possum in NASH? Am J Physiol Gastroinlesl Liver Physiol,2012,303 (1):G9-11

3.Maher JJ. New insights from rodent models of fatly liver disease. Anliox.id Redox Signal, 2011, 15 (2):535-550

4.Matsuzawa N,Takamura T, Kurita S, el al. Lipid-induced oxidative stress causes sleatohepalitis in, mice fed an atherogenic diet. Hepatology, 2007,46 (5):1392-1403

5.Sahai A, Malladi P, Pan X, el al. Obese and diabeti db/db mice develop marked liver fibrosis  in a  model of nonalcoholic steatohepalitis: role of sbortform leptin receptors and osteopontin. Am J Physiol Gastroinlest Liver Pbysiol, 2004,287 (5):Gl035-1043

6.Uno M, Kurita S, Misu H,et al. Tranilast,an anlifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepalitis. Hepatology, 2008, 48 (1) : 109-118

7.Xu Z,Chen L,Leung L,el al. Liver-specific i.naclivalion of the Nrfl gene in adult mouse leads lo nonalcoholic steatobepatilis and hepatic neoplasia. Proc Natl Acad Sci US A, 2005, 15; 102 (11):4120-4125

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Ïû»¯ÏµÍ³Ä£×Ó > »ùÒòÐÞÊÎÐÔÖ¬·¾¸Î¶¯ÎïÄ£×Ó
»ùÒòÐÞÊÎÐÔÖ¬·¾¸Î¶¯ÎïÄ£×Ó

ǰÑÔ

Ö¬·¾¸Î(fatty liver disease,FLD)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔ­ÓÉÒýÆðµÄ¸ÎÔàÖ¬·¾´úлÕϰ­£¬Ö¬ÀàÎïÖʵĶ¯Ì¬Æ½ºâʧµ÷£¬¸Îϸ°ûÄÚÖ¬·¾Èº¼¯¹ý¶àµÄ²¡±ä ¡£Ö¬·¾¸ÎµÄ·¢²¡ÂʽüÄêÀ´Ñ¸ËÙÉÏÉý£¬ÒѳÉΪ½ö´ÎÓÚ²¡¶¾ÐÔ¸ÎÑ׵ĵڶþ´ó¸Î²¡£¬ÕýÑÏÖØÍþв¹úÈ˵Ŀµ½¡ ¡£Æ¾Ö¤²¡Òò£¬Ö¬·¾¸Î¿É·ÖΪ·Ç¾Æ¾«ÐԺ;ƾ«ÐÔÁ½´óÀà ¡£·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(nonalcoholic fatty liver disease, NAFLD)·¢²¡»úÖÆÏÖÔÚÉÐδÃ÷È·£¬ÖÎÁÆÉÏҲȱ·¦ÓÐÓò½·¥£¬ÊÇÏÖÔÚÑо¿µÄÖØµã ¡£¾Æ¾«ÐÔÖ¬·¾¸Î¶¯ÎïÄ£×ÓÒÔÒûʳÓÕµ¼ÎªÖ÷£¬¾Æ¾«¿Éʹ¶¯Îï¸ÎÔàÑõÏûºÄÂÊÔö¸ß£¬ÔöÌíѪñ¼ÑªµÄÑõÏûºÄ£¬´Ó¶øïÔÌ­¶ÔСҶÖÐÐĸÎϸ°ûµÄÑõ¹©£¬ÒýÆð¸ÃÇøÓòµÄ¸Îϸ°ûÍË»¯Ó뻵ËÀ£¬²¢±¬·¢Ö¬·¾±äÐÔ ¡£ÀíÏëµÄÖ¬·¾¸Î¶¯ÎïÄ£×ÓÓ¦ÓëÈËÀàÖ¬·¾ÐԸβ¡µÄÌØÕ÷ÏàËÆ£¬¼´²¡±äÉú³¤Àú³ÌÓÐÏà¶ÔÏÔ×ŵķ֯Ú£¬´Ó´¿´âÐÔÖ¬·¾¸Î¡¢Ö¬·¾ÐÔ¸ÎÑס¢¸ÎÏËά»¯ÖÁ¸ÎÓ²»¯£¬²¢ÇÒÓ¦¾ßÓÐÄ£×ÓÐγÉÂʸߡ¢éæÃüÂʵ͡¢ÔìÄ£ÒªÁìÇáÓ¯Ò×ÐС¢¶ÔʵÑéÖ°Ô±ÎÞº¦¡¢ÔìÄ£×èÖ¹ºó²¡±äÄæ×ª»ºÂý£¬±ãÓÚ¾ÙÐÐÒ©Îï¸ÉÔ¤ÊÔÑéµÈÌØµã ¡£ÏÖÔÚÒѾ­ÔÚ´óÊó¡¢É³Êó¡¢Ð¡Êó¡¢¼ÒÍúÍÖíµÈ¶¯ÎïÖÖÊôÀֳɵؽ¨ÉèÁËÖ¬·¾¸Î¶¯ÎïÄ£×Ó£¬ÕâЩ¶¯ÎïÄ£×ÓΪÃ÷È·Ö¬·¾¸Î·¢²¡»úÖÆ¡¢É¸Ñ¡Ò©ÎïµÈ»ù´¡ºÍÁÙ´²Ñо¿ÌṩÁ˺ܺõÄʵÑ鹤¾ß ¡£

FLD¶¯ÎïÄ£×ÓÖ÷Òª·ÖΪËÄ´óÀࣺ×Ô¾õÐÔÄ£×Ó£¬»ùÒòÐÞÊζ¯ÎïÄ£×Ó£¬Òûʳ¡¢Ò©Îï»ò¶¾ÎïÓÕµ¼Ä£×Ó£¬¸´ºÏÄ£×Ó£¨ÍŽáÓ¦ÓûùÒòÄ£×ÓºÍÓªÑøÄ£×Ó£© ¡£ËüÃÇÔÚ²î±ðµÄ²ãÃæÊ©Õ¹×÷Ó㬵«×îÖÕÖ÷ÒªÊÇͨ¹ýʹ¸ÎÔàÖ¬·¾ÊäÈ루ºÏ³É»òÉãÈ룩ÔöÌí»òÊä³ö£¨É¨³ý£©ïÔÌ­µÄÔ­ÀíÖÆ³É ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

Õë¶Ôµ÷ÖθÎϸ°ûÖ¬·¾´úлµÄÒªº¦»ùÒò£¬Í¨¹ý»ùÒòÐÞÊεÈÒªÁìÒýÆð¸ÎÔàÖ¬·¾´úлÔÓÂÒºÍÑõ»¯Ó¦¼¤£¬µ¼Ö¸ÎÔàÖ¬·¾ÊäÈëºÍÊä³öƽºâʧµ÷ ¡£

¡¾Ä£×ÓÌØµã¡¿£º

CD36Çóý(CD36-/-)СÊóÓÉÓÚ³¤Á´Ö¬·¾Ëá¿çĤתÔËʧµ÷£¬Ö¬·¾ËáÖü´æºÍʹÓÃïÔÌ­60£¥ÒÔÉÏ£¬ÍâÖÜѪÖÐÖ¬·¾Ëá¼°¸ÊÓÍÈýõ¥Ë®Æ½ÏÔÖøÉÏÉý£¬¹ý¶àµÄÖ¬·¾ËáתÔËÖÁ¸ÎÔ࣬Áè¼ÝÆäβ£­Ñõ»¯ÄÜÁ¦£¬ÒýÆð¸ÎÔàÖ¬ÖÊ´úлÔÓÂÒ¼°ÒȵºËضԿ¹£¬ÐγÉFLD ¡£

ÒÒõ£¸¨Ã¸AÑõ»¯Ã¸(acyl-coenzyme A oxidase, AOX)Çóý(AOX-/-)СÊó³¤Á´Ö¬·¾Ëá´úл¼°Ö¬·¾ËáβÑõ»¯Òì³££¬Éúºó1ÖÜ·ºÆðÉ¢ÔÚÐÔ¸ÎÔàÖ¬·¾±äÐÔ£¬2¸öÔÂʱ¸ÎÔàÖ¬·¾±ä³ÊÃÖÂþÐԸı䣬4~5¸öÔÂʱ¸Îϸ°û¹ýÑõ»¯Ã¸ÌåÔöÖ³Îï»î»¯ÊÜÌåα (peroxisome proliferator-activated receptor alpha,PPARa)ϸ°ûÉ«ËØP450 (cytochrome P450, CYP450)¡¢CYP4a10ºÍCYP4a14µÈ»ùÒò±í´ïÔöÇ¿£¬Åãͬ¹ýÑõ»¯ÇâˮƽÉý¸ß£¬6¡«7¸öÔÂʱ¸ÎÔàÖ¬·¾ËáÑõ»¯´ú³¥ÐÔÔöÇ¿£¬¸ÎÔàÖ¬·¾±ä¿ÉÄæ×ª£¬µ«15¸öÔÂʱ¿É²¢·¢HCA»òHCC ¡£

ÏßÁ£ÌåÈý¹¦Ð§ÂѰ×ø(mitochondrial trifunctional protein,MTP)Çóý(MTP-/-£©Ð¡ÊóѪÇåת°±Ã¸Ë®Æ½ËæÄêËêÔöÉϾÙÐÐÐÔÉý¸ß£¬9¡«10¸öÔÂʱ·ºÆð¸ÎÖ¬·¾±ä¡¢¸ßÒȵºËØÑªÖ¢¡¢ÒȵºËضԿ¹¼°ÌÇÄÍÁ¿ÊÜË𣬲¢°éÓиÎÔàÑõ»¯Ó¦¼¤ÔöÇ¿ ¡£

µ°°±ËáÏÙÜÕ×ªÒÆÃ¸1A (methionine adenosyl­transferase-1A, MAT1A)Çóý(MAT1A-/-)СÊó¸ÎÔà¹Èë׸Êëĵȿ¹Ñõ»¯¼Áº¬Á¿½µµÍ£¬¼ÓÈëÖ¬ÖÊÑõ»¯µÄCYP 4a10ºÍ4a14»ùÒò±í´ïϵ÷ ¡£3¸öÔÂʱ·ºÆðÖ¬·¾¸Î¡¢¸Î´ó£¬8¸öÔÂʱ·ºÆð×Ô¾õÐÔÖ¬·¾ÐÔ¸ÎÑ׺ÍÞ²ÂöÖÜΧÑ×Ö¢£¬¸Îϸ°ûÔöÖ³ÏÔ×ÅʱÉõÖÁ¿ÉÄܱ¬·¢HCC ¡£MAT1A-/-СÊó¿ÉÓÃÓÚ̽ÌÖMAT1AÔÚ¸Îϸ°ûÔöÖ³¡¢ËðÉËÒÔ¼°¸ÎÖ×ÁöÐγÉÖеÄ×÷Óà ¡£

¸ÎÔàÌØÒìÐԺ˺ôÎüÒò×Ó1(nuclear respiratory factor 1, NRF1)Çóý(NRF1-/-£©Ð¡Êó4ÖÜÁäʱ·ºÆðÖ¬·¾ÐÔ¸ÎÑײ¢°éÓÐѪÇå¸ÊÓÍÈýõ¥Ë®Æ½Éý¸ß£¬4¸öÔÂʱ²¢·¢Ï¸°ûÖÜΧÏËά»¯£¬10¸öÔÂʱÔò¿É·ºÆðHCA»òHCC ¡£NRF1-/-СÊó¸Îϸ°û»îÐÔÑõˮƽ¡¢Ö¬·¾º¬Á¿ºÍDNAÑõ»¯Ôö¸ß£¬ÊÊÓÃÓÚÑо¿NAFLD·Ö×Ó»úÖÆ¼°ÆäÓëHCCµÄ¹ØÏµ ¡£

¸ÎÔàÌØÒìÐÔPTENÇóý(PTEN-/-)СÊóÔÚ³öÉúºó10ÖÜ¡¢35~40ÖÜ¡¢44ÖÜ¿ÉÏà¼Ì±¬·¢Ö¬·¾ÐÔ¸ÎÑ׸ÎÏËά»¯ÒÔ¼°¸ÎÏÙÁö ¡£74~78ÖÜ66£¥µÄСÊó»á²¢·¢HCC ¡£

Á×ËáÏ©´¼Ê½±ûͪËáôȼ¤Ã¸£­¹Ì´¼µ÷ÀíÒò×ÓÍŽáÂѰ×-1a (phosphoenolpyruvate carboxykinase-sterol regulatory-element binding protein 1a,PEPCK-SREBp­1a)СÊóÓÉÓÚ¸Îϸ°ûÌØÒìÐÔÌ«¹ý±í´ïSREBP-1a£¬³öÉúºó¼´±¬·¢ÔÝʱÐÔÖ¬·¾¸Î ¡£¶ÏÄ̺ó¸øÓèµÍ̼ˮ»¯ºÏÎï¡¢¸ßÂѰ×ÖÊÒûʳ¼¤»îPEPCK£¬ÓÕµ¼¶àÖÖÖ¬·¾ÌìÉúø£¬Ð¡ÊóÔÙ´ÎÐγÉÖ¬·¾¸Î ¡£aP2-NSREBP- 1cСÊóÓëPEPCK-SREBp-1aСÊó±íÐÍÏàËÆ ¡£

 

²Î¿¼ÎÄÏ×£º

1.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000

2.Farrell GC, van Rooyen D. Liver cholesterol: is ii playing possum in NASH? Am J Physiol Gastroinlesl Liver Physiol,2012,303 (1):G9-11

3.Maher JJ. New insights from rodent models of fatly liver disease. Anliox.id Redox Signal, 2011, 15 (2):535-550

4.Matsuzawa N,Takamura T, Kurita S, el al. Lipid-induced oxidative stress causes sleatohepalitis in, mice fed an atherogenic diet. Hepatology, 2007,46 (5):1392-1403

5.Sahai A, Malladi P, Pan X, el al. Obese and diabeti db/db mice develop marked liver fibrosis  in a  model of nonalcoholic steatohepalitis: role of sbortform leptin receptors and osteopontin. Am J Physiol Gastroinlest Liver Pbysiol, 2004,287 (5):Gl035-1043

6.Uno M, Kurita S, Misu H,et al. Tranilast,an anlifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepalitis. Hepatology, 2008, 48 (1) : 109-118

7.Xu Z,Chen L,Leung L,el al. Liver-specific i.naclivalion of the Nrfl gene in adult mouse leads lo nonalcoholic steatobepatilis and hepatic neoplasia. Proc Natl Acad Sci US A, 2005, 15; 102 (11):4120-4125

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿